All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Saxenda weight loss journeys: what TikTok skips over

megan🫶🏼

TikTok creator

9.2K viewsWatch on TikTok→

Quick answer

The creator references Saxenda, the brand name for liraglutide 3mg, an FDA-approved daily injectable GLP-1 receptor agonist indicated for chronic weight management. No clinical claims are made in the transcript itself; the emotional framing in the caption suggests personal response to weight loss outcomes, which is consistent with quality-of-life improvements observed in liraglutide trials such as SCALE (Pi-Sunyer et al., 2015). No dosing, contraindication, or comparative efficacy information is provided by the creator.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.

What did @meganhaskins actually say?

Honestly? Not much, at least not verbally. The transcript is essentially a countdown, some repeated audio, and ambient sound. There are no medical claims, no dosing advice, no before-and-after statistics. The caption does the real communicating here: she's on Saxenda, she's emotional about her results, and she wants followers to "trust the process." That framing, vague but hopeful, is worth examining on its own terms.

The hashtags reinforce the emotional arc: #weightlossjourney, #MentalHealth, #trustthetiming, #forevergrateful. This is not an explainer video. It is a personal experience post, and it should be read as such. No specific claims are made about how much weight she lost, what dose she's on, or why Saxenda worked for her. That's actually refreshing by TikTok wellness standards.

Does the science back this up?

The implicit message, that liraglutide (Saxenda's active ingredient) can produce meaningful, emotional-level life change for people with obesity, is supported by clinical evidence. The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, New England Journal of Medicine) found that participants using 3mg liraglutide daily lost an average of 8.4kg over 56 weeks compared to 2.8kg in the placebo group.

What's less talked about is the psychological dimension. A 2022 analysis published in Obesity Reviews (Blüher et al.) noted that weight loss interventions using GLP-1 receptor agonists were associated with improvements in quality of life scores and emotional wellbeing measures, though causality is hard to untangle from the general effects of weight change itself. So when someone says losing weight on Saxenda made them emotional in a good way, that tracks with what the data suggests happens to patients who respond well.

What did they get wrong (or right)?

There's genuinely nothing factually wrong here, because nothing factual was stated. That's a double-edged observation. On one hand, @meganhaskins avoided the usual TikTok pitfalls: no dosing instructions, no promises of specific results, no claims that Saxenda "fixes" anything. That's more responsible than a large portion of GLP-1 content on this platform.

On the other hand, emotional testimonial content, even without explicit claims, shapes audience expectations in ways that can be misleading. Viewers see someone moved to tears by a medication and may assume similar results are guaranteed. The SCALE trial is clear that roughly 33% of participants on liraglutide lost less than 5% of body weight. Not everyone cries happy tears. The "trust the process" framing doesn't acknowledge that the process fails for a meaningful subset of users, and that's a quiet omission worth naming.

What should you actually know?

Saxenda (liraglutide 3mg) is FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or 27 with at least one weight-related condition. It is a daily injectable GLP-1 receptor agonist, distinct from weekly semaglutide products like Wegovy. The two are sometimes conflated online, which is a real problem for patient understanding.

Common side effects include nausea, vomiting, diarrhea, and constipation, particularly during the dose escalation phase. The FDA label also carries a warning about thyroid C-cell tumors observed in rodent studies, though a direct causal link in humans has not been established. Liraglutide is not a permanent fix: weight regain after discontinuation is well-documented in the literature (Wadden et al., 2020, NEJM Evidence). Starting this medication is a significant clinical decision that requires a licensed provider, not a TikTok comment section.

The bottom line on this video

This post is an emotional personal moment, not a medical tutorial, and it should be evaluated accordingly. The creator made no false claims. The sentiment that Saxenda can produce life-altering results for some patients is consistent with clinical data. But individual testimonials, however genuine, are not evidence of what any given viewer should expect. If you're considering Saxenda because a video made you emotional, that's a fine starting point for a conversation with a provider. It is not a prescription.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Saxenda weight loss journeys: what TikTok skips over, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Saxenda weight loss journeys: what TikTok skips over is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

Compare providers, services and access requirements in the directory before contacting a suitable care team.

Claim verdict

The useful answer behind this video

Claim being checked

The creator references Saxenda, the brand name for liraglutide 3mg, an FDA-approved daily injectable GLP-1 receptor agonist indicated for chronic weight management.

FormBlends verdict

The creator references Saxenda, the brand name for liraglutide 3mg, an FDA-approved daily injectable GLP-1 receptor agonist indicated for chronic weight management. No clinical claims are made in the transcript itself; the emotional framing in the caption suggests personal response to weight loss outcomes, which is consistent with quality-of-life improvements observed in liraglutide trials such as SCALE (Pi-Sunyer et al., 2015). No dosing, contraindication, or comparative efficacy information is provided by the creator.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator references Saxenda, the brand name for liraglutide 3mg, an FDA-approved daily injectable GLP-1 receptor agonist indicated for chronic weight management. No clinical claims are made in the transcript itself; the emotional framing in the caption suggests personal response to weight loss outcomes, which is consistent with quality-of-life improvements observed in liraglutide trials such as SCALE (Pi-Sunyer et al., 2015). No dosing, contraindication, or comparative efficacy information is provided by the creator.
  • Saxenda (liraglutide 3mg) is FDA-approved for chronic weight management and is a daily injectable, not the same as weekly semaglutide products like Wegovy or Ozempic.
  • The SCALE trial (Pi-Sunyer et al., 2015, NEJM) found average weight loss of 8.4kg over 56 weeks on liraglutide, versus 2.8kg on placebo, but roughly 1 in 3 participants lost less than 5% of body weight.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Saxenda (liraglutide 3mg) is FDA-approved for chronic weight management and is a daily injectable, not the same as weekly semaglutide products like Wegovy or Ozempic.
  • The SCALE trial (Pi-Sunyer et al., 2015, NEJM) found average weight loss of 8.4kg over 56 weeks on liraglutide, versus 2.8kg on placebo, but roughly 1 in 3 participants lost less than 5% of body weight.
  • Weight regain after stopping Saxenda is well-documented; Wadden et al. (2020) found substantial regain within months of discontinuation in clinical trial participants.
  • The FDA label for liraglutide includes a boxed warning about thyroid C-cell tumors observed in animal studies; the drug is contraindicated in patients with personal or family history of medullary thyroid carcinoma.
  • Common side effects during dose escalation include nausea, vomiting, and GI distress, which the emotional framing of this video does not address and which matter for patient expectations.
  • No false medical claims were made in this video, which is notable by GLP-1 TikTok standards, but emotional testimonials without context can still shape unrealistic expectations in viewers.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

megan🫶🏼 · TikTok creator

9.2K views on this video

This actually makes me so emotional 🥹 just got to trust the process! #weightlossjouney #positivity #changed #forevergrateful #MentalHealth #trustthetiming #saxenda

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by megan🫶🏼, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.